TORONTO, Sept. 22 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (“Spectral”) today announced the addition of Mr. Guillermo Herrera to its Board of Directors. Mr Herrera joins Mr. R. Ian Lennox (Chairman), Mr. Edward McCormack, Dr. Henry Freisen, Mr. Gordon Peterson, and Dr. Paul Walker on the new Board that was elected at the Company’s annual general meeting on September 14, 2006.
“We are very pleased that Mr. Guillermo Herrera has joined our Board,” stated Dr. Paul Walker, President and CEO of Spectral. “Mr. Herrera is a seasoned, very knowledgeable executive in the global health care sector, with broad operational and commercial experience, including specialty and hospital pharmaceutical products. Mr. Herrera spent 24 years at Abbott Laboratories, most recently serving as Senior Vice President, International Operations and President of Abbott International. In 2004, Mr. Herrera joined Rosetta Partners LLC as the Partner and Principal in charge of the private equity division. He currently serves as President and CEO of NeoPharm, Inc. ,” added Dr. Walker.
“I am delighted to join the Board of Directors of Spectral. I see a significant opportunity to expand the leadership position Spectral has with its unique products, particularly in the area of Sepsis and infectious diseases,” stated Mr. Herrera.
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral’s Rapid 1(TM) West Nile Virus assay and its FDA approved rapid diagnostic for sepsis, the EAA(TM), as well as a range of other biological reagents. Spectral’s common shares are listed on The Toronto Stock Exchange: SDI.
Information in this news release that is not current or historically factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, the future outlook of Spectral and anticipated events or results is assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.
CONTACT: At: Spectral Diagnostics Inc., Dr. Paul Walker, Chief ExecutiveOfficer, (416) 626-3233 ext. 2100
